Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Willow Study of INS1007 in non-cystic fibrosis bronchiectasis
2017-002533-32Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing INS1007 once daily with Placebo once daily (2 arms). Primary endpoint: Time to first pulmonary exacerbation. Started Oct 2017; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2017-002533-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002533-32.